In January 2021, Beijing Targeting One Biotechnology Co., Ltd. (hereinafter referred to as " Targeting One") announced the completion of 150 million round B financing. This round of financing is led by Lilly Asia Fund, followed by China Growth Capital, Hillhouse Capita, and its old shareholders Qingdao Yufeng and Chongyuan Venture Capital, with potential capital as financial consultant. This round of financing will contribute to the further development of Targeting One biological digital PCR technology platform, promote the R & D and clinical trials of a number of innovative molecular diagnostic reagents, promote the application of digital PCR products in life science and clinical fields, and accelerate its commercial layout.
With the increasing demand of tumor liquid biopsy, early screening of tumor, early diagnosis of infectious diseases, rapid diagnosis of severe infection and noninvasive birth defect screening, digital PCR, as a breakthrough "third generation PCR technology", has a huge market space. It has the advantages of single molecule level sensitivity, accurate absolute quantitative analysis, strong anti-interference ability, simple operation and easy standardization. It is one of the most competitive next-generation molecular diagnosis platform technologies, and international giants have deployed it one after another.
Targeting One biology has excellent R & D team, complete intellectual property system, highly competitive digital PCR instrument platform and excellent commercial ability. The company has rapidly built a product line covering the important disease areas such as tumor liquid biopsy, early screening of tumor, early diagnosis of infectious diseases, rapid diagnosis of severe infection and birth defects.
Dr. Yang Wenjun, co-founder of the company said: "we thank Lilly Asia Fund, China Growth Capital and Hillhouse capital for their recognition, and thank the old shareholders for their support as always. In the coming time, Targeting One plans to focus on the digital PCR technology platform for 2-3 years, take the major applications urgently needed in domestic clinical as the guidance, realize the independent and controllable products through continuous technological innovation, and establish an effective operation mechanism of "R & D driven commercial transformation", so as to provide excellent products for scientific researchers, clinicians and patients. "
Chen Fei, managing partner of Lilly Asia Fund said: "as a platform technology, digital PCR has broad application prospects in infectious diseases, tumor fluid biopsy and other important diseases, and is currently in the early development stage of the industry. Targeting One Biology has built a complete set of digital PCR system with independent intellectual property rights covering hardware instruments, chips, raw materials, reagents, software, etc. the product has made key breakthroughs in sensitivity, absolute quantification, stability and anti-interference ability. We are very happy to work with the team to promote the development of clinical application of this technology. "
Xiong Weiming, partner of China Grow Capital, said: "we are very optimistic about the application of digital PCR in tumor liquid biopsy. As a leading enterprise in the field of digital PCR products and academic research, Targeting One Biology believes that it can provide very significant value for clinical tumor diagnosis. At the same time, we are also optimistic about the potential application of the company` s bio digital PCR in NIPT, quantitative detection of infectious diseases, gene therapy, targeted drug resistance and so on. We hope that this round of financing can accelerate the continuous production of excellent clinical products by the team. "
"Digital PCR technology is the third generation of PCR technology, which is a new nucleic acid detection and quantitative method," said the head of biomedicine and medical devices of Hillhouse capital. Compared with the second-generation sequencing and fluorescent quantitative PCR, digital PCR has the advantages of simple operation, controllable quality and high sensitivity. Targeting One is in the leading position in the field of digital PCR. At present, it has developed mature technical products for tumor liquid biopsy, birth defect screening and infectious disease diagnosis, and has made great contributions in the new crown period. We will continue to support the company's original innovation and benefit more patients. "
